brivanib治疗肝癌的临床研究进展
Clicks: 3
ID: 198601
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #77 of 78 articles by views in lontar komputer
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
As an inhibitor of fibroblast growth factor receptor (FGFR)-1, FGFR-2, FGFR-3, vascular endothelial growth factor receptor (VEGFR)-2, and VEGFR-3, brivanib can inhibit tumor angiogenesis and growth. Phase Ⅰ and Ⅱ clinical trials have demonstrated the safety and efficacy of brivanib in the treatment of hepatocellular carcinoma (HCC). However, one phase Ⅲ, randomized, double-blind, placebo-controlled study showed that the overall survival was not significantly improved in patients receiving brivanib as a second-line therapy for advanced HCC, who had failed treatment with sorafenib, than in those receiving placebo. Another phase Ⅲ, randomized, double-blind, controlled study also showed that the overall survival was not significantly improved in patients receiving brivanib as a first-line therapy for HCC than in those receiving sorafenib. Due to the failure of the two phase Ⅲ studies, two other ongoing phase Ⅲ clinical trials had to be discontinued. Subgroup analysis and prior selection of patients with FGF who might benefit from brivanib may be necessary for further investigation of brivanib in the therapy for HCC.
| Reference Key |
xingshun2014linchuangbrivanib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;QI Xingshun |
| Journal | lontar komputer |
| Year | 2014 |
| DOI |
10.3969/j.issn.1001-5256.2014.03.006
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.